Drugs / JMT103
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04630522 | Oct 2020 → Mar 2023 | metastatic carcinoma in the bone | Shanghai JMT-Bio Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03550508 | May 2018 → Aug 2019 | bone neoplasm | Shanghai JMT-Bio Inc. | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04198480 | Jan 2020 → Jul 2021 | humoral hypercalcemia of malignancy | Shanghai JMT-Bio Inc. | Unknown | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05397938 | Jun → Jul 2022 | glucocorticoid-induced osteoporosis | Shanghai JMT-Bio Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT05278338 | Apr 2022 → Dec 2023 | postmenopausal osteoporosis | Shanghai JMT-Bio Inc. | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06221072 | Apr 2024 → May 2027 expected | metastatic carcinoma in the bone | Shanghai JMT-Bio Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JMT103 | “JMT103 is recombinant fully human anti-RANKL monoclonal antibody.” NCT03550508 ↗ |
| Action | Inhibit | “JMT103 demonstrated strong activity through blocking RANKL receptor” NCT03550508 ↗ |
| Modality | Monoclonal antibody | “JMT103 is a novel, full human IgG4 monoclonal antibody targeting RANKL.” NCT03550508 ↗ |
| Route | Subcutaneous | “JMT103 was administered subcutaneously in the upper arm, upper thigh, or abdomen.” NCT03550508 ↗ |
| Target | TNFSF11 | “a novel fully humanized receptor activator of nuclear factor kappa-B ligand (RANKL)-targeting monoclonal antibody” PMID 35992822 ↗ Aug 2022 |